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strial Fibrillation
revious randomized controlled clinical trials of atrial fibril-
ation (AF) patients have failed to demonstrate a benefit of
rhythm control strategy (using cardioversions and/or
rugs) over a rate control strategy (with atrioventricular
AV]-nodal blocking drugs and anticoagulation) (1,2). This
ear brought the first report of a similar trial in AF patients
ith heart failure (3), a particularly important group given
ata from observational studies that heart failure patients
ith AF have an especially poor prognosis compared with
imilar patients in sinus rhythm (4,5). These investigators
nrolled 1,376 patients in a multicenter, randomized un-
linded trial comparing a rhythm control strategy with a
ate control strategy in AF patients with a left ventricular
jection fraction (LVEF) 35% and a history of congestive
eart failure or an ejection fraction (EF)25% (3). Rhythm
ontrol was achieved with cardioversions and either amio-
arone, sotalol, or dofetilide (82% received amiodarone),
nd rate control was achieved with beta-blockers and, if
eeded, digitalis. Over a mean 37  19 months of follow-
p, there were no significant differences in either the
rimary end point of death from cardiovascular causes (27%
n the rhythm control group vs. 25% in the rate control
roup, p  0.59 by the log-rank test) or the secondary
utcomes of overall survival, risk of stroke, or worsening
eart failure (either individually or as a composite). Impor-
antly, although only 27% of the rhythm control group
xhibited prevalent AF at 4 years of follow-up, 58% had at
east one recurrence of AF during follow-up. Therefore, as
ith previous similar studies, it is important to emphasize
hat the hypothesis being tested was whether a rhythm
ontrol strategy is superior to a rate control strategy. It
emains unknown whether actually achieving sinus rhythm
aintenance would result in better outcomes, and we
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Manuscript received April 17, 2009, accepted May 6, 2009.emain limited by the poor efficacy and potential toxicities of
urrent antiarrhythmic drugs.
Important studies were published in 2008 and early 2009
escribing the experience with 2 novel antiarrhythmic
rugs, vernakalant (Cardiome, Vancouver, British Colum-
ia, Canada) and dronedarone (Sanofi-Aventis, Bridgewa-
er, New Jersey). Vernakalant hydrochloride (RSD1235) is
ne of several new agents that takes advantage of the fact
hat some ion channels may be specific to the atria (6). By
locking those more atrial specific ion channels, these new
rugs theoretically reduce or may even eliminate the risk of
entricular proarrhythmia. In 2008, the first phase 3 study of
ne of these agents was described: 356 patients were
andomized in a 2:1 fashion to intravenous vernakalant
ersus placebo for the acute cardioversion of AF (7).
atients were prospectively stratified by duration of AF: 3 h
o 7 days (short duration) and 8 to 45 days (long duration).
eventy-five of 145 vernakalant patients (51.7%) in the
hort duration group converted to sinus rhythm within 90
in (median time to conversion was 11 min in the treat-
ent group) compared with 3 of the 75 placebo patients
4%; p  0.001). Six of the 76 patients in the long duration
roup converted on vernakalant (7.9%) compared with 0 of
he 40 placebo patients (p  0.09). Two of the vernakalant-
reated patients suffered hypotension (neither had a systolic
lood pressure 80 mm Hg and both responded to intra-
enous fluids), but no other significant adverse effects were
een more often in the treatment group than placebo group.
here were no episodes of torsade de pointes or ventricular
rrhythmias during the first 24 h after infusion, an impor-
ant finding given that the half-life of the drug is 2 to 3 h.
lthough the efficacy of this new drug is clearly lower than
hat would be expected with electrical cardioversion, seda-
ion is not necessary. The efficacy appears to be similar to
he most potent intravenous agent available for pharmaco-
ogic cardioversion of AF in the U.S., ibutilide (8,9). As
butilide carries a risk of torsades de pointes (8,9) and other
otentially efficacious agents, such as flecainide and
ropafenone may also result in proarrhythmia or negative
notropy (10,11), this new class of agents may provide a
elatively efficacious way to pharmacologically convert AF
afely. One caveat is that the peri-cardioversion risk of
hromboembolism is thought to be the same whether a
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Year in Review of Electrophysiology August 25, 2009:777–87atient undergoes electrical or pharmacologic cardioversion,
ecessitating consideration of thromboembolic prophylaxis
egardless of the method used (12).
Dronedarone is a multichannel blocker similar to amio-
arone developed for the treatment of AF. Unlike amioda-
one, dronedarone does not contain iodine and therefore
oes not cause iodine-related adverse reactions. Previously,
ronedarone was shown to safely reduce recurrence of AF in
randomized placebo-controlled clinical trials, but patients
ith New York Heart Association (NYHA) functional class
II or IV congestive heart failure were excluded (13). The
hoice of antiarrhythmic drugs in patients with systolic
eart failure is essentially limited to dofetilide and amioda-
one due to the unacceptable toxicities of other agents (12),
nd use of dronedarone may avoid the risk of torsades de
ointes seen with dofetilide and the noncardiac adverse
ffects of amiodarone. In 2008, the ANDROMEDA (An-
iarrhythmic Trial With Dronedarone in Moderate to Severe
ongestive Heart Failure Evaluating Morbidity Decrease)
tudy was published; it was a double-blind, placebo-controlled
rial comparing 400 mg of dronedarone twice daily to
lacebo in patients with NYHA functional class III or IV
ongestive heart failure and a wall-motion index of no more
han 1.2 (approximating an EF of no more than 35%) (14).
lthough a sample size of 1,000 patients was planned, the
rial was terminated after enrolling 627 patients due to an
xcess number of deaths in the dronedarone group. Al-
hough the number of deaths attributed to arrhythmia or
udden death did not differ between treatment and placebo,
ore participants on dronedarone had worsening heart
ailure when they died, and the risk of death on the drug was
ncreased among patients with a lower wall motion index.
he primary end point of all-cause mortality or hospital-
zation for worsening heart failure was not significantly
ifferent between the 2 groups, nor was there a difference in
he prevalence of AF at the 1-month visit. As in previous
tudies, dronedarone significantly reduced creatinine clear-
nce, but this was believed to represent an effect on the
nhibition of specific renal tubular cation transporters rather
han a true reduction in the glomerular filtration rate. Some
ave speculated that the higher creatinine levels may have
rohibited providers from prescribing or optimally dosing
ardioprotective agents such as angiotensin-converting en-
yme (ACE) inhibitors, angiotensin receptor blockers,
nd/or aldosterone in the dronedarone group. For now, the
mplication of this study is that dronedarone should not be
sed in patients with heart failure and left ventricular
ystolic dysfunction.
Published in early 2009, the ATHENA (A placebo-
ontrolled, double-blind, parallel arm Trial to assess efficacy
f dronedarone 400 mg bid for the prevention of Hospital-
zation or death from any cause in patiENts with Atrial
brillation/atrial flutter) study was a randomized, double-
lind, placebo-controlled trial comparing 400 mg of drone-
arone twice daily with placebo in patients with paroxysmal
r persistent AF or atrial flutter, who met at least 1 of the ollowing criteria: age70 years, diabetes, history of stroke,
ransient ischemic attack, systemic embolism, left atrial
iameter 50 mm, and an EF 40% (due to lower
ortality than expected during the study, inclusion criteria
hanged during enrollment to include age 75 years or age
70 years and 1 of these additional risk factors) (15).
YHA functional class IV heart failure was an exclusion
riterion. A total of 4,628 patients were enrolled: 25% were
n AF or atrial flutter at presentation, 60% had evidence of
tructural heart disease, 4% had an EF 35%, and 4% had
YHA functional class III heart failure. Over a mean
ollow-up of 21  5 months, the primary outcome of first
ospitalization or death occurred in 734 (32%) patients in
he dronedarone group and 917 (39%) in the placebo group
p  0.001). The dronedarone group exhibited significantly
ewer hospitalizations (29% vs. 37% in the placebo group,
 0.001), a difference driven primarily by a reduction in
he number of hospitalizations for AF. There was also a
mall, but statistically significant, reduction in acute coro-
ary syndromes in the dronedarone group. Although there
as no significant difference in overall mortality, 63 (3%) of
he dronedarone patients compared with 90 (4%) of the
lacebo patients died of cardiovascular causes (p  0.03), a
ifference driven primarily by fewer deaths due to cardiac
rrhythmia in the dronedarone group (1% vs. 2% in the
lacebo group, p  0.01). Although patients on dronedar-
ne more often developed bradycardia, QT prolongation,
iarrhea, nausea, rash, and an increase in serum creatinine
evels compared with patients on placebo, pulmonary symp-
oms, interstitial lung disease, and abnormalities of thyroid
unction were not significantly more common. An impor-
ant caveat is that the follow-up period may have been
oo short to preclude development of some of these
miodarone-like toxicities in the long term. There was no
vidence of harm in those with NYHA functional class II or
II symptoms or those with a low EF, and differences
ompared with the ANDROMEDA study were attributed
o exclusion of class IV patients and the fact that the
NDROMEDA study included patients with a recent
eart failure exacerbation. Despite the safety found in the
THENA study, the authors warned against use of drone-
arone in patients with severe heart failure and left ventric-
lar dysfunction. The reason for a reduction in cardiovas-
ular death remains unknown; a reduction in acute coronary
yndromes and arrhythmic death suggests that the reduction
ay be due to effects independent of AF prevention, a
otion that fits well with the fact that amiodarone was
riginally developed as an antianginal agent.
In order to answer the question regarding the optimal
onpharmacologic therapy for AF in heart failure, the
ABA-CHF (Comparison of Pulmonary Vein Isolation
ersus AV Nodal Ablation with Biventricular Pacing for
atients with Atrial Fibrillation with Congestive Heart
ailure) study randomized 81 patients with symptomatic
F, NYHA functional class II or III heart failure, an EF
40% to AV node ablation, and biventricular pacing versus
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August 25, 2009:777–87 Year in Review of Electrophysiologyulmonary vein isolation (PVI) using catheter ablation (16).
t 6 months, 88% of the 41 patients in the PVI arm were
ree of AF, although 8 required a second ablation procedure
nd 10 remained on antiarrhythmic drugs. PVI was associ-
ted with groin bleeding in 3 patients, pulmonary vein
tenosis in 2 patients, pericardial effusion in 1 patient, and
ulmonary edema in 1 patient; AV node ablation and
iventricular pacing was associated with lead dislodgement
n 2 patients, pocket hematoma in 2 patients, and pneumo-
horax in 1 patient. End points were measured at 6 months,
nd all patients returned for follow-up. Although AV node
blation and biventricular pacing resulted in mild improve-
ents in the 6-min walk test and the Minnesota Living
ith Heart Failure questionnaire, PVI proved to be the
uperior strategy: PVI resulted in greater improvements in
F, 6-min walk test, and the Minnesota Living with Heart
ailure scores. One caveat to this study is that the mean
eart rate in the AV nodal ablation group was 82  11
eats/min, and this procedure has typically been reserved for
hose who cannot achieve adequate ventricular rate control.
n addition, PVI was performed by experienced ablationists,
nd it is unclear if the success rates of PVI in this population
an be reproduced in usual clinical practice.
entricular Arrhythmias
lthough early repolarization or J-point elevation is com-
only seen on the 12-lead electrocardiograms (ECGs) and
s generally believed to be benign, 2 case control studies in
008 described an association between early repolarization
nd idiopathic ventricular fibrillation (VF). Haïssaguerre
t al. (17) compared ECGs of 206 patients with resuscitated
diopathic VF with those of 412 healthy controls. VF
ubjects were rigorously screened to exclude any underlying
ardiac structural abnormality, ischemia, or evidence of
nown ion channel disorders. Early repolarization was
efined as an elevation of the QRS-ST junction (J-point) of
t least 1 mm (0.1 mV) in at least 2 leads, either as QRS
lurring or notching in inferior or lateral leads; leads V1 to
3 were excluded to avoid inclusion of patients with right
entricular dysplasia or the Brugada syndrome. Although
arly repolarization occurred in 64 (31%) of the VF patients,
t was found in only 5% of controls (p  0.001), a finding
hat remained highly significant after adjusting for potential
onfounders. There are several important caveats to this
tudy. First, the cases included only survivors of VF, hence
he possibility that the ECG findings represent a protective
ffect cannot be excluded. Second, although attempts were
ade to adjust for potential confounders, the controls,
elected from a group of health care professionals, did not
ecessarily rise from the same population as the patients,
eaving open the possibility that ECG differences reflected
ome other unmeasured difference (a problem inherent to
ost case control studies). However, in favor of the hypoth-
sis that early repolarization reflects the underlying patho-
hysiology was the finding that J-point elevation frequently Vncreased compared with baseline before arrhythmic events.
inally, because this was a case control study, this report
ould not comment on the natural question a clinician
ight take away from this study: when confronted with a
atient with early repolarization, what is the risk of VF?
A second study attempted to answer this question. Rosso
t al. (18) found that 45 VF patients with structurally
ormal hearts (43 ultimately diagnosed with idiopathic VF
nd 2 with the Brugada syndrome) more often exhibited
-point elevation than a control group (n  124) matched
or age and gender (42% vs. 13%, p  0.001). In a second
ontrol group of 132 19-year-old noncompetitive athletes,
he proportion with J-point elevation lay in between the
revalence found in patients and controls. As with the
aïssaguerre et al. (17) study, the majority of the J-point
levation observed in VF patients was in the inferior leads.
n contrast, the finding in the young athletes was most
ommon in leads V4 to V6. Based on an estimated risk of
diopathic VF in the general population of those ages 35 to
5 years of 3.4 per 100,000 individuals, the investigators
erived a clinically relevant measure of the positive predic-
ive value using Bayes’ formula of conditional probabilities
19): they estimated that the presence of a J-wave in the
CG of an individual age 35 to 45 years increases the
hances of having idiopathic VF from 3.4 in 100,000 to only
1 in 100,000.
A study published early in 2009 revealed important data
elated to the treatment of idiopathic VF in the setting of
nferolateral early repolarization: of 122 patients with the
yndrome, 33 patients with at least 3 VF episodes before the
nset of antiarrhythmic therapy over a mean follow-up
eriod of 69  58 months were identified for study (20). In
he 16 of these 33 patients with an episode of VF storm
defined as3 episodes in 24 h), none of the following were
ffective: verapamil in 3 patients, lidocaine or mexiletine in
patients, and beta-blockers in 11 patients. Amiodarone
as effective in 3 of 10 patients receiving the drug. Impor-
antly, 7 of 7 VF storm patients responded to isoproterenol:
ll arrhythmias were eliminated when the sinus rate was
ncreased above 120 beats/min. During long-term follow-up
or the entire 33 patients, verapamil, mexilitene, beta-
lockers, 1C agents (including flecainide, propafenone, and
ilsicainide), and amiodarone were generally not effective.
n contrast, quinidine (in 3 patients) or hydroquinidine (in
patients) was totally successful in 9 of 9 patients over a
ean follow-up of 25  18 months. Of interest, these
ffective therapies are consistent with the theory that an
veractive transient outward potassium current (Ito) may be
esponsible for the early repolarization pattern and proar-
hythmia in these patients; Ito is active in early repolariza-
ion, its activity is accentuated with bradycardia (and will
herefore be reduced with isoproterenol), and it is blocked
y quinidine (21).
The search has begun for genetic variants that might
xplain this recently described phenomenon of idiopathic
F with inferolateral early repolarization dubbed “Le Syn-
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Year in Review of Electrophysiology August 25, 2009:777–87rome d’Haïssaguerre” (22). The first report of a rare
enetic variant in a 14-year-old girl with the disease was
eported in early 2009: in this young woman with idiopathic
F and striking J point elevation that varied and was
ccentuated with bradycardia, several genes involved in the
ranscription and regulation of potassium channels, sodium
hannels, calcium channels, calcium binding proteins, and
ytoskeletal proteins interacting with ion channels were
equenced (23). Sequencing of the KCNJ8 gene encoding
he Kir6.1 subunit of the KATP channel identified a mis-
ense variant in exon 3. The variant was absent in 764 alleles
rom healthy controls. Although the current understanding
f this gene suggests that there may be a causal link,
unctional experiments have not yet been performed to more
efinitively demonstrate a cause-effect relationship or details
egarding the mechanism. Given the absence of the variant
n 156 additional patients with idiopathic VF and early
epolarization, the culprit gene variants affecting the major-
ty of these patients remain unknown.
Building on data that a witnessed cardiac arrest treated
ith an immediately available automatic external defibrilla-
or (AED) could be effective (24,25) and that most cardiac
rrests occur in the home (26), investigators performed the
AT (Home External Defibrillator Trial) (27). There were
,001 participants with a history of an anterior wall myo-
ardial infarction but not meeting current indications for an
mplantable cardioverter-defibrillator (ICD), who were ran-
omized in equal proportions to receive an AED for home
se or no AED. All participants had to have a spouse or
ompanion willing to call emergency medical services,
erform cardiopulmonary resuscitation (CPR), and use an
ED. Both study groups received video-based CPR train-
ng; those randomized to the AED were instructed to place
call for assistance and perform CPR after application of
he AED (if more than 1 rescuer was present, these tasks
ere to occur simultaneously). Of the 450 patients who died
ver a median follow-up of 37.3 months, 228 (6.5%) were in
he control group and 222 (6.4%) were in the AED group
p  0.77). The primary outcome did not differ among any
f the multiple pre-specified subgroups. Only 169 of 450
eaths (37.6%) were deemed to be caused by a tachyarrhyth-
ia consistent with ventricular tachycardia (VT) or VF, and
nly 160 were from sudden cardiac arrest (defined as a
udden loss of consciousness requiring cardiopulmonary
esuscitation or transthoracic defibrillation). Of those 160,
nitial collapse occurred in the home in 117; of those 117,
nly 58 (50%) were witnessed. Of the 38 patients resusci-
ated from sudden cardiac arrest and surviving for at least
8 h, 19 were in the control group and 19 were in the AED
roup. Correlative documentation of AED rhythms was
vailable for 21 of 29 unresponsive patients in the AED
roup; a shock was advised for 13 of these and delivered in
2 (in 1 case, the device was inadvertently turned off). Of
he 12 patients, 4 were long-term survivors. There were no
ocumented inappropriate shocks. There are several poten-
ial explanations for the overall negative result: first, the dverall mortality and incidence of sudden cardiac arrest were
ubstantially lower than anticipated, resulting in less power
han initially projected to detect a difference between the
roups; all participants in the control group received CPR
raining, including frequent reminders, which likely im-
roved outcomes in those not receiving AEDs; and only
ne-half of the sudden arrest events that occurred at home
ere witnessed.
Late 2008 and early 2009 brought 3 important studies
xamining the predictive value of microvolt T-wave alter-
ans (MTWA) in the 3 main populations typically consid-
red for primary prevention ICDs. MTWA is a noninvasive
est of arrhythmia vulnerability that has shown some prom-
se in predicting which patients may benefit from an ICD
28–30). Of note, previous studies have been largely obser-
ational, and the value of the test has generally been in its
egative predictive value (if it is normal, the risk is low)
28,31). Gold et al. (32) published a prospective substudy of
he SCD-HeFT (Sudden Cardiac Death in Heart Failure
rial), in which 490 of the 2,521 patients with an EF35%
nd NYHA functional class II or III heart failure, random-
zed in equal proportions to ICD therapy, amiodarone, or
lacebo, underwent MTWA testing. In short, MTWA did
ot predict the composite primary end point of the first
ccurrence of any of the following: sudden cardiac death
SCD), sustained VT or VF, or appropriate ICD discharge.
lthough the authors acknowledged that insufficient power
ould not be excluded as an explanation for their negative
ndings, the study was quite large relative to previous
tudies, the duration of follow-up was likely adequate, and
he 10% primary event rate in MTWA-negative patients
uggests that this test is unlikely to be useful in risk
tratifying patients meeting SCD-HeFT criteria. Similarly,
egative results were found in the MASTER (Microvolt T
ave Alternans Testing for Risk Stratification of Post MI
atients) trial, a study in which 575 patients meeting
ADIT-II criteria (an earlier myocardial infarction and EF
30%) underwent MTWA testing and ICD implantation
33). Over a mean 2.1 0.9 years, MTWA testing failed to
iscriminate between those who did and did not ultimately
xperience SCD or an appropriate ICD discharge. Of
nterest, total mortality was significant greater in MTWA
on-negative (either positive or indeterminate results) pa-
ients than in those with a normal result (hazard ratio: 2.04,
 0.02). Finally, the ABCD (Alternans Before Cardio-
erter Defibrillator) trial addressed the MUSTT (Multi-
enter Unsustained Tachycardia Trial) population: 566
atients with an EF 40% attributable to ischemic heart
isease and nonsustained VT underwent MTWA and
nvasive electrophysiological testing (EPS) with pro-
rammed ventricular stimulation (34). ICD insertion was
andated in all patients with either positive MTWA or
PS. The primary end point was first appropriate ICD
ischarge or SCD. The positive predictive value was poor
or both tests. The study fulfilled the main objective in
emonstrating that the negative predictive value of
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August 25, 2009:777–87 Year in Review of ElectrophysiologyTWA, found to be 95% for predicting events at 1 year,
as not inferior to the negative predictive value of EPS.
owever, because 55% of patients had discordant results, it
oes not appear that MTWA should serve as a substitute for
PS. The authors suggested the 2 tests may be complemen-
ary in this patient population: the event rate in patients
ith 2 normal tests (MTWA and EPS both normal) was
pproximately 3-fold lower than in patients with 1 abnormal
est and approximately 6-fold lower in patients with 2
bnormal tests. The 1-year event rate was 3% for those with
normal tests. Despite the publication of these important
tudies, the role of MTWA in clinical practice remains
ncertain; although the positive predictive value is clearly
ot useful, the utility of the test used in conjunction with
thers to aid in risk stratification likely requires further
tudy.
enetic Arrhythmia Syndromes
mportant basic as well as clinical advances continue to be
eported for patients with genetic arrhythmia syndromes.
nterest in this area has greatly expanded; for example,
ubMed lists 96 citations in 2008 for just the long-QT
yndrome (LQTS) alone. It will be obviously not possible to
iscuss all the important new studies.
QTS
QTS is due to abnormalities in ion channel function.
ost abnormalities involve the delayed rectifier k chan-
els, less commonly the Na channel and very rarely the
-type calcium channel. It is will known that abnormalities
n the IKs (slow k delayed rectifier current) channel
LQT1) are enhanced by catecholamines. Novel insights
nto the mechanism of impaired channel function by stres-
ors were reported by Seebohm et al. (35). Reaction to stress
nvolves production of cortisol, which in turn regulates
xpression of the gene serum- and glucocorticoid-inducible
inase (SGK1), which in turn enhances the IKs current.
his is normally done by enhanced insertion of KCNQ1
alpha subunit) and KCNE1 (beta subunit) into the channel
embranes (36). Seebohm et al. (35) showed altered SGK1
egulation of some IKs mutant channels. Some mutant
hannels showed paradoxically reduced IKs current by
GK1. This effect was induced by downregulation of
ecycling of the IKs channels. The authors’ findings provide
ey insights relative to the proarrhythmia effects of stressor
ormones on IKs channel function and help explain the
dverse clinical response to stressors (i.e., exercise, swim-
ing, emotional upsets).
Another important paper (37) related to a rather rare
orm of the LQTS called the Timothy syndrome or LQT8.
his rare disease is manifest by QT prolongation, SCD,
utism, webbed fingers and toes, and immune deficiencies.
hree genetic mutations have been identified that result in
lowed inactivation of the L type Ca current. (38)
ncreased cytosolic Ca results in prolongation of the QT onterval and predisposes to triggered arrhythmia. Thiel et al.
37) infected rat cardiomyocytes with mutant L-type Ca
Cav1.2) channels. These myocytes showed decreased inac-
ivation, prolongation of the action potential duration, and
fter-depolarizations. They found that this mutation re-
ulted in increased calcium/calmodulin-dependent protein
inase II (CaMKII), which results in enhanced Ca
elease from the SR, enhanced Ca influx, and slowed
nactivation. Inhibition of CaMKII with an inhibitory
eptide completely reversed the above abnormalities. These
tudies clearly showed the critical role of CaMKII in the
enesis of this syndrome. A very thoughtful accompanying
ditorial (39) expanded on the potential implications of
hese findings relative to other disorders that involve abnor-
alities in Ca metabolism.
linical Studies
n excellent “state-of-the-art” paper by Goldenberg and
oss (40) is recommended. In addition, an interim report
rom the international LQTS registry provided long-term
ollow-up information for patients older than 40 years of
ge (41). The study involved 2,759 subjects with mean
ollow-up time (after age 40 years) of 19  13.5 years.
linical data were obtained prospectively and included
etailed symptoms, annual ECGs, treatment, and genetic
esting. The authors defined the risk factors for death or
borted sudden death. For example, females with a cor-
ected QT interval 470 ms had a cumulative risk rate of
6%. Other risk factors included a history of syncope within
years, and the most powerful predictor was for those with
QT3 genotype. Before this study it was felt that patients
ith the LQTS who survived to age 40 years were at
elatively low risk for fatal events. This important study
ocumented the substantial risk for those with the above-
numerated risk factors.
There is continued interest in finding more effective
reatment modalities for those with the LQTS. Experimen-
al studies showed that the antianginal agent ranolazine
oth blocks IKr as well as the late Na current. Wu et al.
42), using an in vitro guinea pig model, showed this drug
educed action potential duration and ventricular arrhyth-
ia by agents that mimic the LQT3 syndrome. In a recent
tudy, Moss et al. (43) showed that in patients with LQT3
ue to the KPQ deletion mutation, ranolazine infusions
ignificantly shortened the corrected QT interval and sup-
ressed myocardial relaxation in these patients.
atecholaminergic Polymorphous VT
very important observation was reported by Cerrone et al.
44) involving a mutant mouse model of catecholaminergic
olymorphic ventricular tachycardia (CPVT). This syn-
rome is associated with exercise-induced premature ven-
ricular complexes, bidirectional VT, polymorphic VT, and
F. The authors used an elegant epicardial and endocardial
ptical mapping system in mice with a knockin mutation of
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or chemical subendocardial ablation. They found that this
odel replicated the cardiac arrhythmias observed clinically
nd could be repeated in single cell Purkinje preparation
after-depolarizations and triggered activity). This impor-
ant seminal observation found that the His-Purkinje sys-
em was a source of arrhythmias in a CPVT mouse model.
olecular Biology and Genetics of AF
amilial AF has been long recognized. A large survey from
ayo Clinic, Rochester, Minnesota showed that 36% of
94 patients had lone AF and among those, 15% had a
amilial history (45). A great deal of recent work has
dentified the link between a number of genes and AF. This
nformation has led to development of a number of possible
athogenetic mechanisms of AF. An excellent review by
sai et al. (46) is recommended. The genesis of AF appears
o be dependent on triggers (often from the pulmonary
eins) as well as a suitable atrial substrate. Modification of
trial structure and function appears after prolonged rapid
trial rate, which results in abnormalities in cycle length-
ependent shortening of the atrial effective refractory pe-
iod. Maintenance of AF appears to be dependent on factors
hat encourage generation of wavelets in the atrium. The
ave length is the distance traveled by an electrical impulse
uring 1 refractory period (conduction velocity  refractory
eriod). The safety margin for conduction in a re-entrant
ircuit is determined by the difference between the path
ength of the circuit and the wave length. Therefore, factors
hat result in decreases in action potential duration or
onduction velocity will favor atrial wavelets and hence will
erve to stabilize AF. Other important factors involve
hanges in the atrial substrate (i.e., fibroses) that tend to
tabilize atrial wavelets (in conduction slowing or block).
ole of the k Channel
he first genetic abnormality causing AF was described in a
-generation Chinese family and a mutation of the KCNQ1
ene (responsible for the IKs current), resulting in a gain of
unction of the k channel (47). The same group (48)
escribed a familial form of AF involving KCNE2, the beta
ubunit for the k channels. Again this mutation produces
gain of function of the k channel.
Of note were the discovery of 2 additional familial genes
ssociated with mutations that produced overexpression of
he Kir2.1 channel with enhanced IK1 current (49) and
verexpression of the KCNH2 gene, which resulted in a
ain of function of IKr.
All of the above-described k genes associated with
amilial AF showed properties of enhanced k currents and
ecreased action potential duration. As discussed above,
ecreased atrial refractoriness would serve to promote mul-
iple wave re-entry and AF. Recently, Ellinor et al. (50)
ound no mutations in KCNJ2 or KCNE genes in 96
robands of a Caucasian population with AF. The k shannel abnormalities may, therefore, be more prevalent in
hinese people.
Another interesting paradox relating to atrial k channel
unction was reported by Olson et al. (51). They found a
amilial form of AF associated with early onset of symptoms
efractory to drugs and ablation, associated with a nonsense
utation in KCNA5, which encodes Kv1.5 responsible for
he atrial selective Ikur current. Expression studies showed
ailure to generate the Ikur current and action potential
rolongation with after-depolarizations in human atrial
yocytes.
These authors further demonstrated enhanced suscepti-
ility to AF in a mouse model. This interesting study
ntroduced a novel mechanism for genetic induction of AF
nvolving loss of function of an atrial selective k channel
ith lengthening of the action potential duration and
roducing an atrial variant of “torsades.”
ole of the Na Channel
everal sparse reports documented a familial association
etween “loss of function” caused by SCN5A mutation with
F, cardiac conduction system disease, and sick sinus
yndrome or with AF and cardiomyopathy (52,53). A recent
ery interesting observation described the association of a
ovel mutation of the SCN5A gene (M1875T), which was
ssociated with “gain of function of the Na channel” (54).
ain of function of the Na channel has been well
ocumented as a cause of one of the long-QT syndromes
LQT3), but in these patients the QT interval was normal.
he mutant channel by expression studies was found to
how a gain of function in relation to steady-state inactiva-
ion kinetics but there was no persistent Na channel
urrent. The authors speculated that the prolonged atrial
ction potential leads to atrial-triggered activity. Benito
t al. (55) described a mutation in the SCN5A gene
ssociated with both AF and the LQT variant. Of clinical
nterest was the positive response of these patients with
espect to AF control with use of flecainide, a drug that is a
otent Na channel blocker.
The largest genetic study examining the relationship
etween AF and SCN5A mutations was provided by
arbar et al. (56). They sequenced the entire coding region
n 375 patients with either lone (n  118) or cardiac-
ssociated AF (n  257). They found that 5.9% showed an
ssociation between AF and rare SCN5A variants. In 10
atients, 8 novel variants were identified; in 12, SCN5A
ariants previously associated with other syndromes (i.e.,
QTS, Brugada) were found. Ellinor et al. (57) also
eported a link between SCN5A mutations and AF. In
ddition, Chen et al. (58) studied 157 patients with early-
nset AF and 314 matched controls. They found an
ssociation between common SCN5A polymorphisms
with loss of function) and nonfamilial lone AF. They
peculated that loss of Na channel current results in
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August 25, 2009:777–87 Year in Review of Electrophysiologyecreased upstroke velocity, a shorter wave length, and
ence, promotion of AF.
linical Implications
he early finding of an association between familial AF and
ain of function of only k channels has to be modified.
ore recent observations have documented an association
etween AF and genetic mutations that result in loss of
unction of the k channel (increased action potential
uration and delayed after depolarization) (59), as well as
hose associated with both loss and gain of function of the
a channels. These findings open up exciting new ther-
peutic avenues to help correct for the genetic deficiency.
his was, for example, fruitfully applied in use of flecainide
or familial AF associated with gain of function of the Na
hannels (55). There is continued interest in the association
f AF with upstream genetic mutations. Candidate genes
nvolved in the renin-angiotensin system genes (60) (angio-
ensin II is known to be profibrotic) have been studied. In
ddition, there is continued interest in genes controlling the
xpression of connexin 40. Genetic variations producing
ecreased expression of connexin 40 can lead to impaired
onduction and block, which may facilitate AF (61). Previ-
us studies by Gollob et al. (62) emphasized the importance
f somatic mutations of the connexin 40 gene and the
enesis of AF. These exciting advances in our understand-
ng of the links between genetic mutations and AF open up
variety of novel clinical strategies (i.e., use of anti-
nflammatory agents or blockers of the renin-angiotensin
ystem) in selected individuals.
mplantable Devices
n the past year, there were no pivotal clinical trials that
ould redefine or expand the use of devices in clinical
ractice. Two proof-of-concept clinical trials failed to show
ardiac resynchronization therapy (CRT) benefit in patients
ith heart failure and narrow QRS complexes and in
atients with mild heart failure (63,64). Subgroup analysis
f data from previous published seminal trials (65,66),
owever, revealed an alarming negative association of ICD
hocks with patient mortality that may affect our practice
pproach (67,68). The search for better patient selection for
CD and CRT continued (69–73). There were no new
evice recalls and safety alerts, although the Sprint Fidelis
igh-voltage leads from Medtronic (Minneapolis, Minne-
ota), which were placed on Food and Drug Administration
ecall in October, 2007 continue to be an active problem
74,75). The American College of Cardiology/American
eart Association/Heart Rhythm Society published the
ew 2008 Guidelines for Device-Based Therapy of Cardiac
hythm Abnormalities (76). In this part of the review, we
ill examine how some of the published works may affect
ur approach to device implantation and clinical practice.
CD. Post-hoc analyses were performed on the MADIT II
Multicenter Automatic Defibrillator Implantation Trial II) dnd the SCD-HeFT to examine the prognostic significance
f appropriate and inappropriate ICD shocks. Daubert et al.
65) reported that the all-cause mortality of patients in
ADIT II who received appropriate and inappropriate
hocks (but not antitachycardia pacing [ATP]) was 4 times
igher than for those without shock therapy. In particular,
nappropriate shocks (occurring in 11.5% of the patients)
ncreased all-cause mortality 2-fold. Atrial fibrillation (44%)
nd supraventricular tachycardia (36%) were the major
riggers for inappropriate shocks. In the SCD-HeFT, pa-
ients who received shocks for any arrhythmia had a
ignificantly higher risk of death (progressive heart failure
eing the most common cause) than those who did not
eceive shocks (64). Even 1 single appropriate ICD shock,
s compared with no appropriate shock, increased the
ortality rate nearly 6-fold. Inappropriate shocks occurred
n 17.4% of the patients and, similar to MADIT II results,
n inappropriate shock increased the mortality rate nearly
-fold. The risk of death increased as much as 16-fold in
atients who had more than 2 appropriate and 1 inappro-
riate shock. The patients who received appropriate shocks
ad a lower EF, a higher NYHA functional class, and were
ore likely to have AF. Available data demonstrated an
ssociation between shocks and increased mortality only and
id not suggest any mechanism or a causal relationship.
esides adverse psychological consequences, direct damage
o the myocardium is the most apparent explanation for the
bserved association between shocks and increased mortal-
ty. However, in the case of appropriate shocks, it is
onceivable that, as a patient’s medical status approaches the
nd stage, serious ventricular tachyarrhythmias (especially
ccurring near the time of death) are expected to increase.
hese arrhythmias, presumably less likely to be successfully
reated by ATP, will require more appropriate shock ther-
py, thereby creating an association, but not a causal
elationship, between increased mortality and appropriate
hocks.
Although a causal relationship has yet to be determined,
he association of shocks with increased mortality in primary
revention is potentially alarming and must be recognized
y physicians who care for these patients (77). Clinicians
ust familiarize themselves with all the available device
etection and therapy algorithms to formulate program-
ing strategies to minimize inappropriate shocks while
elivering shocks for life-threatening situations only. For
xample, a higher detection rate would decrease the number
f shocks delivered; a longer detection-to-shock duration
ould allow some VT/VF that would otherwise result in
hock delivery to terminate spontaneously. Use of morphol-
gy discrimination should be a part of the regular detection
riteria, especially in patients with AF and single chamber
CD. Extending ATP to a faster rate may reduce shock
herapy. Remote monitoring will help to identify inappro-
riately detected tachyarrhythmias that can be treated med-
cally or with ablation before inappropriate shocks are
elivered. Optimizing therapy for AF, especially in rate
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Year in Review of Electrophysiology August 25, 2009:777–87ontrol, and congestive heart failure that are often linked to
entricular tachyarrhythmias or shocks may have a poten-
ially added beneficial effect on the prognosis of these
atients by reducing shock instances.
The safety and possibly favorable outcomes of the above
rogramming strategies were evaluated by the PREPARE
Primary Prevention Parameters Evaluation) study (67).
omparing them with a historical control cohort, the
nvestigators showed that a standard detection and treat-
ent protocol with the above key programming elements
educed the morbidity index. In particular, shocks for any
ause and inappropriate shocks were reduced and the
ncidence of untreated VT and arrhythmia syncope were
imilar between the study patients and the control cohort.
lthough the study patients had a lower mortality rate
ompared with the control cohort (4.9% vs. 8.7%), the
ifference was not statistically significant once the differ-
nces in patient baseline characteristics (more PREPARE
atients were taking beta-blockers, had shorter QRS dura-
ion and higher LVEF and nonbiventricular ICD) were
ncluded in the analysis. Prospective randomized trials are
urely needed to confirm if there is a causal relationship
etween shocks (and magnitude of energy delivered) and
ncreased mortality, and whether strategic programming
imed to reduce shocks will result in a mortality benefit.
In view of the negative impact of even 1 single shock on
ortality, one has to ask if shocks delivered during defibril-
ation threshold testing (DFT) at the time of implant are
etrimental to patients who receive ICD for primary pre-
ention. The necessity for DFT has been questioned
78,79). A recent subgroup analysis of the SCD-HeFT data
ndicated that successful defibrillation was achieved with
10 J and 30 J in 86.8% and 100%, respectively, of the
atients tested during device implantation (67). Further-
ore, low defibrillation energy at implant did not predict
ong-term mortality or shock efficacy. Based on these
esults, a strong argument could be made to eliminate DFT
t implant in this group of patients (80). However, until
ata show that successful treatment outcomes can be
chieved even when implant DFT is greater than the
aximal ICD output, the prudent approach is to continue
o perform DFT but limit it to 1 test shock when possible.
n the other hand, in view of the above studies, one may
sk if DFT should be performed during generator replace-
ent in the primary prevention patients who have had a
atisfactory safety margin at the initial implant.
In order to further identify patients with low LVEF who
ould benefit most with ICD implantation, the MADIT II
nvestigators used subset regression analysis to create a
imple risk scores for risk stratification (68). After separat-
ng a group of very high-risk patients (blood urea nitrogen
50 mg/dl and/or serum creatinine 2.5 mg/dl), a clinical
isk scoring system made up of 5 clinical factors (NYHA
unctional class II, age 70 years, blood urea nitrogen
26 mg/dl, QRS 012 s, and AF) was developed. Low-
isk (score  0) and very high-risk patients received no cortality benefit from ICD implantation. The former had
ery low mortality (8% over 2 years), even without ICD
espite a low LVEF; the latter had such high mortality
50% over 2 years) from multiple comorbidities that ICD
ailed to affect outcomes. However, ICD benefit was most
ronounced in patients with risk scores of 1 or 2 (2-year
ortality was reduced from 22% to 27% to 10% to 15%).
ICD therapy was reappraised in 2 state-of-the-art reviews
81,82). Focusing primarily on the negative data, Tung et al.
81) opined that the clinical benefit of ICD therapy was
verestimated in the clinical trials. The authors argued that:
) The ICD treatment arm benefited from the underper-
ormance (oftentimes, detrimental) of antiarrhythmic drugs
omprising the control arms; 2) in most primary and
econdary prevention trials, when compared with subjects in
he control arm, more ICD patients were treated with
eta-blockers, whose beneficial effects on arrhythmic and
ll-cause mortality had been well documented; 3) the
dverse effects on morbidity and mortality, quality of life,
otential proarrhythmia from ICD therapy, and device
alfunction have been underestimated; 4) the published
ost-effective analyses represented hypothetical “best-case
cenario” estimates and did not accurately reflect real-world
gures; and 5) some of the published implant guidelines
ere based on statistically insignificant results and often
ailed to take into account changes in standard practice since
he publication of the clinical trials. However, despite these
ssertions, the authors concluded that ICD therapy has been
learly shown to be effective in aborting sudden arrhythmic
eath. In an accompanying editorial, Epstein (83) addressed
he authors’ concerns by redirecting the readers’ attention to
he many undisputable ICD benefits established by multiple
linical trials. In his review on the use of ICD after
yocardial infarction, Myerburg (82) discussed some of the
actors that should be considered in selection of patients for
CD therapy. The use of LVEF of 35% in the published
ractice guidelines was questioned. Although clinical trials
et a maximum upper limit on LVEF (mostly 35%) for the
nrollment criterion, the median values of patients in the trials
ere substantially lower. Subgroup analyses of MADIT,
ADIT II, and SCD-HeFT data indicated that patients
ith LVEF 30% did not benefit from ICD therapy. The
uthors suggested that heart failure, ambient nonsustained
nd induced VT, QRS interval 120 ms, and deteriorating
VEF over time may improve patient selection within a
iven range of LVEF.
RT
ince last year’s review, there were 2 proof-of-concept
linical trials on CRT indications. The RethinQ (Cardiac
esynchronization THerapy IN patients with heart failure
nd narrow QRS) study investigated if symptomatic heart
ailure patients (NYHA functional class III) with echocar-
iographic evidence of left ventricular mechanical dyssyn-
hrony and systolic dysfunction (LVEF 35%) but narrow
Q
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August 25, 2009:777–87 Year in Review of ElectrophysiologyRS complexes (130 ms) would benefit from CRT (63).
t 6 months, there were no differences between the CRT
roup and the non-CRT group in the primary end point of
n increase in peak oxygen consumption. Quality of life
core, 6-minute walk distance, and LVEF were not differ-
nt. The REVERSE (Resynchronization reverses Remod-
ling in Systolic left vEntricular dysfunction) study asked if
ildly symptomatic (NYHA functional class I and II) heart
ailure patients with reduced LVEF (40%), increase LV
nd-diastolic diameter 55 mm, and prolonged QRS du-
ation (120 ms) would benefit from CRT (64). Not surpris-
ngly, during a 12-month period, CRT did not improve
eart failure symptoms or mortality despite echocardio-
raphic evidence of reversed remodeling by CRT. Although
RT significantly delayed the time-to-first heart failure
ospitalization, the absolute reduction was small (at 12
onths, about 7% of the control group was hospitalized vs.
% of the CRT group). This small benefit was more than
ffset by the high peri-operative (4%) and post-operative
16%) system-related complications. One should also con-
ider that this group of patients will live with an implanted
evice for a longer period of time, which exposes them to
ore device replacement, potentially more generator and
ead malfunctions, and shocks. Until more convincing
utcomes data are available, benefits from CRT are most
vident in moderate-to-severe heart failure patients with LV
ystolic dysfunction and prolonged QRS duration only.
It is well recognized that even among this group of “best”
andidates, more than one-third of patients did not respond
o CRT (84,85). A number of small observational reports
ave suggested that echocardiographic measurements may
redict response to CRT. A multicenter prospective trial
PROSPECT [Predictors of Response to CRT]) clearly
stablished that an elaborate set of echocardiographic pa-
ameters of dyssynchrony failed to improve patient selection
70). Thirty-one percent of the patients failed to show
mprovement of clinical composite score and 44% showed a
15% decrease in LV end-systolic volume. The role of
chocardiography in either patient selection or adjustment
f pacing parameters is questionable; the search for other
eterministic factors continues (86).
evice Recall
n October 2007, the Food and Drug Administration
laced the Medtronic Sprint Fidelis high-voltage leads on
lass I recall because of a high incidence of fracture involving
he pace-sense conductor (90%) or the high-voltage coil
onductor (10%). Fractures can occur suddenly, resulting in
versensing and clusters of inappropriate shocks, which can
e proarrhythmic and may have long-term negative effects
n mortality in view of the connection between shocks and
ortality. Kallinen et al. (74) reported that oversensing and
nappropriate shocks often occurred very shortly after or
ven before impedance changes were detected. A download-
ble self-programming Lead Integrity Alert (LIA) algo-ithm was introduced by Medtronic to address this problem
75). When the device detects an abnormal change in lead
mpedance or nonphysiological noise (ultra-short VV inter-
als), self-reprogramming will be initiated to minimize
hock delivery before the patient can obtain medical help.
he programming changes include: 1) an increase of the
etection duration (the number of intervals to detect, VF is
hanged to 30 of 40); 2) emission of an audible alert every
h (instead of once daily); and 3) transmission of an alert
essage to the Medtronic Carelink Network Website,
here it can be read by the patient’s physician, if the
enerator is capable of wireless transmission.
Whether this approach will reduce the number of inap-
ropriate shocks and ensure patient safety in clinical practice
emains to be documented. The weakest link is in prompt
otification. For nonwireless devices, the alert process is
ntirely dependent on the ability of the patients (many of
hom are old and hearing impaired) to hear the audible
lert. Furthermore, as pointed out in the accompanying
ditorial, the algorithm has only been simulated with
istorical data (87). Nevertheless, this self-programmable
unctionality may be a first step in need-based or
ondition-based approaches in dynamic device and dis-
ase management.
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niversity of California San Francisco, 500 Parnassus Avenue, Box 1354,
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